ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina
a presente invenção refere-se aos compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, em que as variáveis r1, r2, r3, r4, r5 e a são como definidas aqui; processos para a preparação de intermediários usados na preparação de; e composições contendo tais compostos e sais, e seus...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | por |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | JAMISON BRYCE TUTTLE SIMONE SCIABOLA JACLYN LOUISE HENDERSON TRAVIS T. WAGER JOSEPH MICHAEL YOUNG BETHANY LYN KORMOS PATRICK ROBERT VERHOEST NANDINI CHATURBHAI PATEL JOSEPH WALTER TUCKER THOMAS ALLEN CHAPPIE |
description | a presente invenção refere-se aos compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, em que as variáveis r1, r2, r3, r4, r5 e a são como definidas aqui; processos para a preparação de intermediários usados na preparação de; e composições contendo tais compostos e sais, e seus usos para o tratamento de distúrbios mediados por d3 (ou associados com d3) incluindo, por exemplo, vício de substância, abuso de substância, esquizofrenia (por exemplo, seus sintomas cognitivos), comprometimento cognitivo (por exemplo, comprometimento cognitivo associado com esquizofrenia ad, ou pd), doença de parkinson, mania, ansiedade, distúrbios de controle de impulso, distúrbios sexuais e depressão.
The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_BR112018013955A2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BR112018013955A2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_BR112018013955A23</originalsourceid><addsrcrecordid>eNrjZHDLyUxPzCtJLVZISVVIyS9IzM3MS1RIMQZxzXTMdSx0LHVLUkuKEnUzMlOK8nVNM3QLMosyU_KjjXSMdVNiE6tSC4A6eBhY0xJzilN5oTQ3g6qba4izh25qQX58anFBYnJqXmpJvFOQoaGRgaGFgaGxpampo5ExseoAWNcyYg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina</title><source>esp@cenet</source><creator>JAMISON BRYCE TUTTLE ; SIMONE SCIABOLA ; JACLYN LOUISE HENDERSON ; TRAVIS T. WAGER ; JOSEPH MICHAEL YOUNG ; BETHANY LYN KORMOS ; PATRICK ROBERT VERHOEST ; NANDINI CHATURBHAI PATEL ; JOSEPH WALTER TUCKER ; THOMAS ALLEN CHAPPIE</creator><creatorcontrib>JAMISON BRYCE TUTTLE ; SIMONE SCIABOLA ; JACLYN LOUISE HENDERSON ; TRAVIS T. WAGER ; JOSEPH MICHAEL YOUNG ; BETHANY LYN KORMOS ; PATRICK ROBERT VERHOEST ; NANDINI CHATURBHAI PATEL ; JOSEPH WALTER TUCKER ; THOMAS ALLEN CHAPPIE</creatorcontrib><description>a presente invenção refere-se aos compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, em que as variáveis r1, r2, r3, r4, r5 e a são como definidas aqui; processos para a preparação de intermediários usados na preparação de; e composições contendo tais compostos e sais, e seus usos para o tratamento de distúrbios mediados por d3 (ou associados com d3) incluindo, por exemplo, vício de substância, abuso de substância, esquizofrenia (por exemplo, seus sintomas cognitivos), comprometimento cognitivo (por exemplo, comprometimento cognitivo associado com esquizofrenia ad, ou pd), doença de parkinson, mania, ansiedade, distúrbios de controle de impulso, distúrbios sexuais e depressão.
The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.</description><language>por</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2018</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20181211&DB=EPODOC&CC=BR&NR=112018013955A2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76418</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20181211&DB=EPODOC&CC=BR&NR=112018013955A2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>JAMISON BRYCE TUTTLE</creatorcontrib><creatorcontrib>SIMONE SCIABOLA</creatorcontrib><creatorcontrib>JACLYN LOUISE HENDERSON</creatorcontrib><creatorcontrib>TRAVIS T. WAGER</creatorcontrib><creatorcontrib>JOSEPH MICHAEL YOUNG</creatorcontrib><creatorcontrib>BETHANY LYN KORMOS</creatorcontrib><creatorcontrib>PATRICK ROBERT VERHOEST</creatorcontrib><creatorcontrib>NANDINI CHATURBHAI PATEL</creatorcontrib><creatorcontrib>JOSEPH WALTER TUCKER</creatorcontrib><creatorcontrib>THOMAS ALLEN CHAPPIE</creatorcontrib><title>ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina</title><description>a presente invenção refere-se aos compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, em que as variáveis r1, r2, r3, r4, r5 e a são como definidas aqui; processos para a preparação de intermediários usados na preparação de; e composições contendo tais compostos e sais, e seus usos para o tratamento de distúrbios mediados por d3 (ou associados com d3) incluindo, por exemplo, vício de substância, abuso de substância, esquizofrenia (por exemplo, seus sintomas cognitivos), comprometimento cognitivo (por exemplo, comprometimento cognitivo associado com esquizofrenia ad, ou pd), doença de parkinson, mania, ansiedade, distúrbios de controle de impulso, distúrbios sexuais e depressão.
The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2018</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHDLyUxPzCtJLVZISVVIyS9IzM3MS1RIMQZxzXTMdSx0LHVLUkuKEnUzMlOK8nVNM3QLMosyU_KjjXSMdVNiE6tSC4A6eBhY0xJzilN5oTQ3g6qba4izh25qQX58anFBYnJqXmpJvFOQoaGRgaGFgaGxpampo5ExseoAWNcyYg</recordid><startdate>20181211</startdate><enddate>20181211</enddate><creator>JAMISON BRYCE TUTTLE</creator><creator>SIMONE SCIABOLA</creator><creator>JACLYN LOUISE HENDERSON</creator><creator>TRAVIS T. WAGER</creator><creator>JOSEPH MICHAEL YOUNG</creator><creator>BETHANY LYN KORMOS</creator><creator>PATRICK ROBERT VERHOEST</creator><creator>NANDINI CHATURBHAI PATEL</creator><creator>JOSEPH WALTER TUCKER</creator><creator>THOMAS ALLEN CHAPPIE</creator><scope>EVB</scope></search><sort><creationdate>20181211</creationdate><title>ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina</title><author>JAMISON BRYCE TUTTLE ; SIMONE SCIABOLA ; JACLYN LOUISE HENDERSON ; TRAVIS T. WAGER ; JOSEPH MICHAEL YOUNG ; BETHANY LYN KORMOS ; PATRICK ROBERT VERHOEST ; NANDINI CHATURBHAI PATEL ; JOSEPH WALTER TUCKER ; THOMAS ALLEN CHAPPIE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_BR112018013955A23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>por</language><creationdate>2018</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>JAMISON BRYCE TUTTLE</creatorcontrib><creatorcontrib>SIMONE SCIABOLA</creatorcontrib><creatorcontrib>JACLYN LOUISE HENDERSON</creatorcontrib><creatorcontrib>TRAVIS T. WAGER</creatorcontrib><creatorcontrib>JOSEPH MICHAEL YOUNG</creatorcontrib><creatorcontrib>BETHANY LYN KORMOS</creatorcontrib><creatorcontrib>PATRICK ROBERT VERHOEST</creatorcontrib><creatorcontrib>NANDINI CHATURBHAI PATEL</creatorcontrib><creatorcontrib>JOSEPH WALTER TUCKER</creatorcontrib><creatorcontrib>THOMAS ALLEN CHAPPIE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>JAMISON BRYCE TUTTLE</au><au>SIMONE SCIABOLA</au><au>JACLYN LOUISE HENDERSON</au><au>TRAVIS T. WAGER</au><au>JOSEPH MICHAEL YOUNG</au><au>BETHANY LYN KORMOS</au><au>PATRICK ROBERT VERHOEST</au><au>NANDINI CHATURBHAI PATEL</au><au>JOSEPH WALTER TUCKER</au><au>THOMAS ALLEN CHAPPIE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina</title><date>2018-12-11</date><risdate>2018</risdate><abstract>a presente invenção refere-se aos compostos de fórmula (i): e sais farmaceuticamente aceitáveis dos mesmos, em que as variáveis r1, r2, r3, r4, r5 e a são como definidas aqui; processos para a preparação de intermediários usados na preparação de; e composições contendo tais compostos e sais, e seus usos para o tratamento de distúrbios mediados por d3 (ou associados com d3) incluindo, por exemplo, vício de substância, abuso de substância, esquizofrenia (por exemplo, seus sintomas cognitivos), comprometimento cognitivo (por exemplo, comprometimento cognitivo associado com esquizofrenia ad, ou pd), doença de parkinson, mania, ansiedade, distúrbios de controle de impulso, distúrbios sexuais e depressão.
The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | por |
recordid | cdi_epo_espacenet_BR112018013955A2 |
source | esp@cenet |
subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A38%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=JAMISON%20BRYCE%20TUTTLE&rft.date=2018-12-11&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EBR112018013955A2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |